Pulmonx Hits Growth Milestone: 6% Revenue Increase in Q3 2026
Pulmonx, a leading innovator in lung cancer treatment, has achieved a significant milestone in its third quarter of 2026. The company has reported a 6% increase in total worldwide revenue to $22.8 million, marking its return to revenue growth.
According to Glenn French, President and Chief Executive Officer of Pulmonx, this milestone is evidence of the company's strategy in action. "Our continued progress, built on consistent execution, leaves us increasingly confident in our ability to achieve our previously communicated revenue guidance of $90 million-$92 million for the full year 2026," French stated during the Q3 earnings conference call.
One of the key factors driving Pulmonx's growth is its disciplined execution of high-impact selling activities. The company has emphasized setting up efficient valve programs, engaging with physicians who treat COPD and educating service line administrators to ensure a high-quality patient experience. As a result, Pulmonx delivered 7% year-over-year growth in the U.S. market.
The company's efforts have paid off in terms of adjusted EBITDA loss reduction as well. Pulmonx reported a nearly 60% decrease in its adjusted EBITDA loss to $3.5 million compared to the prior year period. Derrick Sung, Chief Operating Officer and Chief Financial Officer, will provide further details on this later in the call.
Pulmonx's growth milestone is also attributed to its commitment to expanding clinical initiatives. The company has been working on advancing market-expanding clinical initiatives, which are expected to drive future growth. With a solid foundation of revenue growth and reduced losses, Pulmonx is well-positioned to achieve its full-year 2026 guidance.
French expressed confidence in the company's strategy and progress: "I am very pleased to report that Pulmonx delivered total worldwide revenue of $22.8 million in the third quarter of 2026... This milestone is evidence of our strategy in action."
Pulmonx's focus on disciplined execution, market-expanding clinical initiatives, and commitment to reducing losses has positioned the company for future success. The company's return to revenue growth and reduced adjusted EBITDA loss are significant achievements that demonstrate its ability to execute its strategy effectively.
